최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.30 no.4, 2020년, pp.250 - 258
정태현 (전남대학교 약학대학) , 서승민 (전남대학교 약학대학) , 송현진 (플로리다 대학교 약학대학) , 전나경 (전남대학교 약학대학)
Background: Dopamine receptor agonists (DRAs) have been associated with impulse control disorders (ICDs) in Parkinson's disease (PD) in preliminary studies. Whether the association holds true when DRAs are used to treat non-PD, such as restless legs syndrome, prolactinoma, and several mood disorders...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Kim J, Yu Y. A psychological approach on impulse control disorder criminal. Korean Crim Psychol Rev 2015;11(3):53-76.
Leroi I, Harbishettar V, Andrews M, McDonald K, Byrne EJ, Burns A. Carer burden in apathy and impulse control disorders in Parkinson's disease. Int J Geriatr Psychiatry 2012;27(2):160-6.
Callesen MB, Scheel-Kruger J, Kringelbach ML, Moller A. A systematic review of impulse control disorders in Parkinson's disease. J Parkinsons Dis 2013;3(2):105-38.
Molde H, Moussavi Y, Kopperud ST, Erga AH, Hansen AL, Pallesen S. Impulse-control disorders in Parkinson's disease: a meta-analysis and review of case-control studies. Front Neurol 2018;9:330.
Gatto EM, Aldinio V. Impulse control disorders in Parkinson's disease. A brief and comprehensive review. Front Neurol 2019;10:351.
Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63(7):969-73.
Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 2015;69(4):183-9.
Rizos A, Sauerbier A, Antonini A, et al. A european multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 2016;23(8):1255-61.
Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, et al. Dopamine agonists and impulse control disorders: A complex association. Drug Saf 2018;41(1):19-75.
Schreiber L, Odlaug BL, Grant JE. Impulse control disorders: updated review of clinical characteristics and pharmacological management. Front psychiatry. 2011;2:1.
Ohayon MM, O'Hara R, Vitiello MV. Epidemiology of restless legs syndrome: A synthesis of the literature. Sleep Med Rev 2012;16(4):283-95.
Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005;8(1):3-6.
Sucharew H, Macaluso M. Methods for research evidence synthesis: The scoping review approach. J Hosp Med 2019;14(7):416-8.
Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol 2005;8(1):19-32.
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.
Voon V, Schoerling A, Wenzel S, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol 2011;11(1):117.
Bayard S, Langenier MC, Dauvilliers Y. Decision-making, rewardseeking behaviors and dopamine agonist therapy in restless legs syndrome. Sleep 2013;36(10):1501-7.
Heim B, Djamshidian A, Heidbreder A, et al. Augmentation and impulsive behaviors in restless legs syndrome: Coexistence or association? Neurology 2016;87(1):36-40.
Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med 2011;12(1):34-40.
Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med 2012;13(10):1280-5.
Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med 2018;169(7):467-73.
Kolla BP, Mansukhani MP, Barraza R, Bostwick JM. Impact of dopamine agonists on compulsive behaviors: A case series of pramipexole-induced pathological gambling. Psychosomatics 2010;51(3):271-3.
Driver-Dunckley ED, Noble BN, Hentz JG, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007;30(5):249-55.
Cornelinus J. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010;33(1):81-7.
Mishima T, Fujioka S, Kurisaki R, et al. Impulse control disorders and punding in Perry syndrome. Parkinsonism Relat Disord 2015;21(11):1381-2.
Tajima-Pozo K, Bardudo E, Aguilar-Shea AL, Papanti D. Paraphilia as adverse drug reaction to dopamine agonist (Pramipexole). Acta Neuropsychiatr 2011;23(2):89.
Strejilevich SA, Martino DJ, Igoa A, Manes F. Pathological gambling in a bipolar patient treated with pramipexole. J Neuropsychiatry Clin Neurosci 2011;23(1)E2-3.
Maruo J, Haraguchi Y, Tateishi H, et al. Abnormal behaviours during pramipexole treatment for Cotard's syndrome: a case report. Psychogeriatrics 2016;16(4):283-6.
Larson ER. Neuropsychological findings in a case of punding before and after cessation of pramipexole. Clin Neuropsychol 2015;29(1):166-78.
Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 2018;91(3):e189-201.
Lizarraga KJ, Fox SH, Strafella AP, Lang AE. Hallucinations, delusions and impulse control disorders in Parkinson disease. Clin Geriatr Med 2019;36(1):105-18.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.